Stroke Finder Helmet Part 1 - Acute Care of Stroke Patients
more
![]() ![]()
2017
Equipment Grant
|
![]() ![]()
2017
Project Grant
|
![]() ![]()
2017
Project Grant
|
![]() ![]()
2017
Project Grant
|
![]() ![]()
2016
Project Grant
|
![]() ![]()
2014
Project Grant
|
![]() ![]()
2013
Project Grant
|
![]() ![]()
2013
Fellowship
|
![]() ![]()
2013
Project Grant
|
![]() ![]()
2013
Project Grant
|
![]() ![]()
2013
Project Grant
|
![]() ![]()
2013
Project Grant
|
![]() ![]()
2012
Project Grant
|
![]() ![]()
2011
Scholarship
|
![]() ![]()
2011
Project Grant
|
![]() ![]()
2010
Scholarship
|
![]() ![]()
2010
Project Grant
|
![]() ![]()
2010
Project Grant
|
![]() ![]()
2009
Project Grant
|
![]() ![]()
2009
HMRI Award for Research Excellence
|
![]() ![]()
2008
Project Grant
|
![]() ![]()
2007
Fellowship
|
![]() ![]()
2007
Project Grant
|
![]() ![]()
2007
Project Grant
|
![]() ![]()
2006
Project Grant
|
![]() ![]()
2004
Project Grant
|
![]() ![]()
2003
Project Grant
|
![]() ![]()
2003
Project Grant
|
![]() ![]()
2000
Fellowship
|
![]() ![]()
1998
Project Grant
|
The John Hunter Hospital Stroke Unit and Acute Stroke Research Group were founded in 1999 and the group is now nationally and internationally recognised as leaders in the development of new strategies in acute stroke imaging and therapies. Activities span from experimental laboratory research through to community-based studies and health systems implementation. The generation of new knowledge and its translation to improve health care outcomes for stroke sufferers is being realised with the Hunter now being one of the international leading sites for implementation of clot busting therapies for stroke.
When I began my clinical career in neurology there were no effective acute stroke therapies. The pressing need to be able to help acute stroke sufferers drove my interest in both the discovery of new treatments and the translation of those treatments into the real world of clinical care.
To provide the best, most advanced research based clinical care for acute stroke sufferers and to discover and implement new ways of preventing stroke.
Conjoint Professor Chris Levi is the Director of Clinical Research and Translation - Research Innovation and Partnerships and Co-Director of Acute Stroke Services at John Hunter Hospital, Hunter New England Local Health District. He has a clinical and research passion for improving outcomes of patients who are affected by stroke and Transient Ischemic Attacks (TIA).
Stroke is the leading cause of long term adult disability and is the second leading cause of death, both in Australia and globally. Professor Levi is part of a world-recognised team who are working to transform the clinical treatment of stroke and give the 50,000 Australians who are affected each year a better recovery.
Since arriving back in Newcastle in 1999 to establish the John Hunter Hospital Stroke Unit and Research Group, Professor Levi has made a number of ground-breaking discoveries and led prestigious clinical trials and studies. One of the major advances in recent years is the trial of the new clot-busting drug for treatment of stroke called Tenecteplase, co-led by Professor Chris Levi and Professor Mark Parsons.
Professor Levi is also researching a number of other aspects of stroke to try and improve outcomes for patients. He is investigating genetic factors that may predispose someone to having a stroke so that it can hopefully be prevented and treatment can be tailored accordingly.
Optimising the triage protocol for stroke patients so that they receive the right care straight away is another important aspect of research and evidence based practice for Professor Levi and his team. Many treatments for stroke are highly dependent on the time at which they are administered after the onset of stroke and therefore an effective triage strategy could make all the different for a patient. Thanks to initiatives such as this, Newcastle is far above the national average in treatment times for stroke patients, raising the bar from approximately 5 per cent of patients around the country that are treated in time to receive clot-busting drugs to around 20-30 per cent in Newcastle.
Professor Levi is a highly respected clinical researcher with >250 peer-reviewed publications and over 160 invited talks and sessions chaired at major national and international meetings, as well as extensive experience serving on steering committees of major clinical trials. His strong international reputation is supported by publications in preeminent journals such as Nature Genetics, New England Journal of Medicine and The Lancet.
Christopher Levi, Prof Michael Nilsson, Prof Mark Parsons, A/Prof Rohan Walker
Stroke Finder Helmet Part 1 - Acute Care of Stroke Patients
moreA/Prof Frini Karayanidis, Dr Patrick Cooper, Dr Aaron Wong, Dr Andrew Bivard, Prof Chris Levi
Transient ischemic attack (TIA) is clinically defined as a self-limiting neurological event with full functional recovery within 24 hours. However, new evidence indicates that as many as 68% of TIA sufferers show subtle, sustained cognitive impairment that can have direct consequences for daily living. Patient-reported symptoms, such as mental fatigue, anxiety/depression, and difficulty returning to work, point to specific impairment of cognitive control.
moreThe proposed project is highly significant because it will, for the first time, to accurately map the changes that occur in the brain following stoke and identify patters for good clinical outcomes.
moreDr Elizabeth Holliday, Rodney Scott, Christopher Levi, John Attia
Genetic risk factors, gene expression and ischaemic stroke
moreDr Renate Thienel, Frini Karayanidis, Juanita Todd, Peter Stanwell, Mark Parsons, Chris Levi
Mapping networks in the brain
moreDr Ashley Kable, Amanda Baker, Dimity Pond, Alyna Turner, Chris Levi, Carolyn Hullick
Evaluating transitional care - When a stoke patient goes home
moreProfessor Christopher Levi, J. Sturmm, Mark Parsons, Neil Spratt, A. Loiselle, B. O'Brien, V. Zenteno, L.Holliday, Rodney Scott, J. Maguire
Stroke is the leading cause of long-term disability in Australia and the second leading cause of death.
moreThis funding was provided to fund the vanguard phase of two clinical trials in stroke:
moreDr Damien McLeod, Dr Neil Spratt, Associate Professor Mark Parsons, Professor Chris Levi
Dr Frini Karayanidis, Mark Parsons, Chris Levi, Grant Bateman, Patricia Michie, Peter Schofield & Todd Jolly
Dr Frini Karayanidis, Mark Parsons, Chris Levi, Grant Bateman, Patricia Michie, Peter Schofield & Todd Jolly
Dr Frini Karayanidis, Mark Parsons, Patricia Michie, Christopher Levi, Sharna Jamadar, Matthew Hughes, Peter Schofield, Dr Grant Bateman
Associate Professor Christopher Levi, John Attia, Rodney Scott, Michael Seldon, Lisa Lincz, Jon Sturm
Dr Neil Spratt, Dr Mark Parsons, Dr Damian McLeod; Conjoint Associate Professor Christopher Levi
Dr Timothy Budd, Dr Mark Parsons, Dr Chris Levi
Dr Mark Parsons, Dr Bill Budd, Dr Chris Levi
Dr Christopher Levi, Professor Mike Calford, Dr Mark Parsons
Dr Neva Bull, Associate Professor M Hunter, Chris Levi
Dr Christopher Levi, Dr J Lowe
Dr Christopher Levi, Dr Julia Lowe